Targeting specific proteins to treat multiple myeloma
Official title: Targeting chromatin acetylation factors in multiple myeloma
Funded at Massachusetts General Hospital · NIH-11046875 · Data updated 2026-11-12
This study is looking at new ways to treat multiple myeloma by targeting certain proteins that help the cancer cells grow, and it’s designed for people who are affected by this type of cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | March 1, 2025 |
| Project end | February 28, 2030 |
| Funding year | 2025 |
| Award (this year) | $623,120 |
| NIH project number | 1R01CA288855-01A1 |
| Project ID | NIH-11046875 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults diagnosed with multiple myeloma, particularly those who have not responded well to existing treatments.
✕Less likely to help
Patients with other types of cancer or those who do not have multiple myeloma may not benefit from this research.
What this research studies
This research focuses on multiple myeloma, a type of cancer that affects plasma cells in the blood. The team is developing new chemical tools that can degrade specific proteins, known as CBP and p300, which are crucial for the growth and survival of myeloma cells. By using advanced techniques to study how these proteins can be targeted, the researchers aim to find more effective treatment strategies. The project will involve laboratory experiments and animal models to test the effectiveness of these new treatments.
Why it matters
Potential benefit: If successful, this research could lead to more effective therapies for patients with multiple myeloma, potentially improving survival rates and quality of life.
How similar studies have gone: Other research has shown promise in targeting chromatin regulators for cancer treatment, suggesting that this approach may be effective.
Where this research is happening
-
Massachusetts General Hospital
Boston, United States Active
Researchers
- Principal investigator: Ott, Christopher J — Massachusetts General Hospital
- Study coordinator: Ott, Christopher J
Related research
Other NIH-funded projects on the same topics.
-
Integrative study of multiple myeloma genetics and disease biology
A team at Dana-Farber and partners is pursuing a long-term project to understand the genetic and molecular drivers of multiple myeloma and how treatments interact with disease biology.
-
Comparative Modeling to Prevent, Detect Early, and Treat Multiple Myeloma
A research team will build and compare computer models to understand how multiple myeloma develops, can be detected earlier, and treated more effectively.
-
How LDL Affects Multiple Myeloma: New Pathways to Keep Remission
A new grant is studying how cholesterol from LDL particles fuels multiple myeloma and how this interaction influences the tumor environment and immune response, with goals to help patients stay in remission.
-
Therapy-induced senescence and immune activation in multiple myeloma
A study in people with multiple myeloma will explore how treatment-related senescence in cancer cells may stimulate the immune system and affect cancer return after standard frontline therapy.
-
BCMA CAR-T enteritis: understanding immune toxicities in multiple myeloma
A broad study to uncover why some CAR-T cell treatments targeting BCMA cause severe intestinal inflammation in people with multiple myeloma.
-
Understanding Drug-Resistant Multiple Myeloma to Stop Relapse
Researchers are studying why some myeloma cells resist treatment and how to create new therapies to prevent relapse.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.